GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Amphetamine Sulfate Tablets USP, 5 mg and 10 mg28-01-2021
28-01-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholding for the Period Ended December 31, 2020
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here20-01-2021
Glenmark Pharmaceuticals Q3 PAT seen up 27.4% YoY to Rs. 190.8 cr: Prabhudas Lilladher
Net Sales are expected to increase by 5.5 percent Y-o-Y (down 4.3 percent Q-o-Q) to Rs. 2,638.6 crore, according to Prabhudas Lilladher.18-01-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 014140 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer18-01-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ("SEBI LODR")
The Company wishes to inform that the Company has on 15 January 2021 redeemed U.S. $10,000,000 in aggregate principal amount of its 2021 Notes, representing approximately 5.00% of the aggregate principal amount of the 2021 Notes at the time of initial listing. As on the date of this announcement, no amount is outstanding in connection with the 2021 Notes.15-01-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ("SEBI LODR")
This is in furtherance to our earlier letters, we wish to inform you that Glenmark Pharmaceuticals Limited ('Company') has issued a notice of optional redemption to the holders of U.S. $200 million 4.5% Senior Notes due 2021 ('Notice') listed on the Singapore Exchange Securities Trading Limited, in accordance with the terms of the Indenture dated as of August 1, 2016 (as amended, supplemented, waived or otherwise modified from time to time), between, among others, the Company and Citicorp International Limited, as trustee. Copy of the Notice is attached herewith. Capitalised or other terms used but not defined herein shall, unless the context otherwise requires, have the meanings as set out in the Notice. We request you to kindly take this intimation on record and to treat the same as compliance with the applicable provisions of the SEBI LODR.04-01-2021
Glenmark Pharma gets USFDA nod for erectile dysfunction treatment drug
Glenmark Pharmaceuticals Ltd has received final approval from the United States Food and Drug Administration (USFDA) for Tadalafil tablets USP in the strengths of 2.5 mg, 5 mg, 10 mg and 20 mg, the company said in a regulatory filing.31-12-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and 30 mg31-12-2020
Glenmark launches fixed dose combination drug for diabetes
The drug contains Remogliflozin (100 mg) and Vildagliptin (50 mg) in a fixed-dose and must be taken twice daily to improve glycemic control in patients, the company added.29-12-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India29-12-2020